Overview

* Cardiff Oncology ( CRDF ) Q3 net loss is smaller-than-expectations, reflecting better operational performance

* Company's Q3 operating expenses decreased due to reduced clinical trial expenses

* Cardiff maintains cash runway into Q1 2027, with $60.6 mln in cash and investments

Result Drivers

* POSITIVE TRIAL DATA - Phase 2 trial of onvansertib shows 19% improvement in ORR for 30mg cohort vs standard care

* TRIAL TOLERABILITY - Onvansertib continues to be well-tolerated with no major toxicities

* COMMERCIAL OPPORTUNITY - Onvansertib positioned to address significant medical need with 150,000 new CRC patients annually in the U.S.

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $120,000

Royalty

Revenue

Q3 Net Beat -$11.26 -$13.70

Income mln mln (8

Analysts

)

Q3 Beat -$11.97 -$14.30

Income mln mln (8

from Analysts

Operatio )

ns

Q3 Basic -$0.17

EPS

Q3 $12.09

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Cardiff Oncology Inc ( CRDF ) is $10.00, about 77.6% above its November 5 closing price of $2.24

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)